When was Imara founded?

Imara was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Imara located?

Imara is headquartered in Cambridge, United States. It is registered at Cambridge (United States).

Who is the current CEO of Imara?

James McArthur and Rahul Ballal s of Imara. James McArthur is also angel investors in 2 startups.

How many employees does Imara have?

As of Apr 30, 2026, the latest employee count at Imara is 10.

Is Imara a funded company?

Imara is a funded company, having raised a total of $94M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 14, 2016.

When was the latest funding round of Imara?

Imara's latest funding was a $***** Series B round on Mar 18, 2019, with participation from 9 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $584M in funding in 2026 to date.

Where does Imara rank among its competitors?

Imara ranks 8th amongst 29 active competitors, of which 5 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Editas Medicine, which secured $2M in Dec, 2023.

Who are the top competitors of Imara?

Imara's top competitors include Editas Medicine, LogicBio and Kedrion. Among them, Editas Medicine secured the most recent funding round in December, 2023.

Imara - 2026 Company Profile, Team, Funding, Competitors & Financials

Imara is a public company based in Cambridge (United States), founded in 2016 by James McArthur. It operates as a Small molecules to treat rare blood diseases such as sickle cell disease. Imara has raised $94M in funding from investors like New Enterprise Associates, Orbimed and Bay City Capital. The company has 29 active competitors, including 5 funded and 11 that have exited. Its top competitors include companies like Editas Medicine, LogicBio and Kedrion.

Company Details

Imara is developing novel therapeutics for patients suffering from sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and becomes damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Its lead candidate is IMR-687, a small molecule inhibitor of phosphodiesterase-9 (PDE9i) for the treatment of sickle cell disease.

Website: imaratx.com
Social
Email ID: *****@imaratx.com
Registered Address: Cambridge (United States)

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Public

Total Funding

$94M in 2 rounds

Latest Funding Round

Series B, Mar 18, 2019, $*****

Investors

New Enterprise Associates & 8 more

Ranked

8^th among 29 active competitors

Employee Count

10 as on Apr 30, 2026

Similar Companies

Editas Medicine & 41 more

Exit Details

Public

View Imara's full profile

Imara is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IMARA INC. CIN: 1672619 , United States, Active		-	-	-
Imara Inc CIN: 81-1523849 , United States, Active	Jan 25, 2016	-	41 (As on Dec 31, 2021)	-

Imara got listed on Mar 12, 2020.

Click here to take a look at Imara's IPO in detail

Imara has raised a total funding of $94M over 2 rounds. Its first funding round was on Apr 14, 2016. Its latest funding round was a Series B round on Mar 18, 2019 for $*****. 9 investors participated in its latest round. Imara has 9 institutional investors.

Here is the list of recent funding rounds of Imara:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 18, 2019	4649485	Series B	8062963	1262014	5688078	5427960
Apr 14, 2016	5616126	Series A	6472348	3651108	New Enterprise Associates & 4 more	6544081

Access funding benchmarks and valuations. Sign up today!

View details of Imara's funding rounds and investors

The founders of Imara is James McArthur. Rahul Ballal is the CEO of Imara.

Here are the details of Imara's key team members:

James McArthur: Founder & President & CEO of Imara and founder of 1 other company. They are also an angel investor in 2 startups and serve on the board of 1 company.
Rahul Ballal: CEO of Imara.

View details of Imara's Founder profiles and Board Members

Imara's employee count trend

Imara has 10 employees as of Apr 26. Here is Imara's employee count trend over the years:

Uncover Imara's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Imara include Editas Medicine, LogicBio and Kedrion. Here is the list of Top 10 competitors of Imara, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Editas Medicine 2013, Cambridge (United States), Public	Developer of therapeutics for rare genetic diseases	$210M	Fidelity Investments, Deerfield & 21 others	63/100
2nd	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Orbimed & 5 others	60/100
3rd	Kedrion 2001, Barga (Italy), Acquired	Developer of plasma-derived products for hemophilia and immune system deficiencies	$189M	CDP Equity, Ampersand Capital & 4 others	60/100
4th	GBT 2011, San Francisco (United States), Acquired	Developer of small molecules for the treatment of sickle cell disease	$88.7M	Wellington, RA Capital Management & 8 others	58/100
5th	Cyclerion 2018, Cambridge (United States), Public	Developer of therapies for treating sickle cell disease and diabetic nephropathy	-	Lincoln Park Capital, Invus & 6 others	58/100
6th	Octapharma 1983, Lachen (Switzerland), Unfunded	Developer of plasma derived therapeutics for multiple diseases	-	-	54/100
7th	Modus Therapeutics 2011, Stockholm (Sweden), Series B	Developers of polysaccharide based drug for the treatment of Sickle Cell Disease	$22.9M	Healthcap, The Foundation for Baltic and East European Studies ... & 4 others	53/100
8th	Imara 2016, Cambridge (United States), Public	Small molecules to treat rare blood diseases such as sickle cell disease	$94M	RA Capital Management, Orbimed & 7 others	51/100
9th	Sierra Oncology 2003, Vancouver (Canada), Acquired	Developer of targeted therapies to treat cancer	$75M	Vivo Capital, Adams Street Partners & 18 others	51/100
10th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	Mitsubishi UFJ Capital, E&Investment & 4 others	50/100